Bayer: Liver Neoplasms trials

The registry lists 15 Liver Neoplasms studies with Bayer as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 3Phase 3 4No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsCompletedNCT04696055Phase 2Results posted
• Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.CompletedNCT01043523Results posted
• Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)CompletedNCT00692770Phase 3Results posted
• Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)CompletedNCT00494299Phase 3Results posted
• A Research Study to Treat Patients With Advanced Hepatocellular CarcinomaCompletedNCT00108953Phase 2Results posted
• A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00105443Phase 3Results posted
• A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular CarcinomaCompletedNCT00044512Phase 2Results posted
• Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line TreatmentTerminatedNCT03644511
• Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1
• Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)CompletedNCT03289273
• HCC Patient Preferences in JapanCompletedNCT02616692
• Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in ChinaCompletedNCT01839630
• Sorafenib in Hepatocellular Carcinoma Clinical Practice in ItalyCompletedNCT01539681
• GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study StartWithdrawnNCT01191385
• Identification of Hepatic LesionsCompletedNCT00307866Phase 3